Seoul National University Biomedical Research Institute
Seoul, South Korea
NCT Number: NCT03882112
Primary objective
- To evaluate food effect on the pharmacokinetics (PK) of a single oral dose of HIP1601 in healthy subjects under fed or fasting condition.
Secondary objectives
* To explore food effect on the pharmacodynamics (PD) of single oral dose of HIP1601 in healthy subjects under fed or fasting condition. * To evaluate the safety of single oral dose of HIP1601 in healthy subjects under fed or fasting condition.
Looking for future studies?
Notify Me19 year–50 year
All sexes
Interventional
Phase 1
Seoul, South Korea
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Single dosing of HIP1601 40mg, orally
Other names: HIP1601
Time frame: Blood sampling during 24 hours after administration
Maximum observed concentration after dose
Time frame: Blood sampling during 24 hours after administration
Area under the plasma concentration versus time curve from dosing to the last quantifiable concentration
Time frame: Blood sampling during 24 hours after administration
Time of Cmax over the time span specified
Time frame: Blood sampling during 24 hours after administration
Area under the plasma concentration versus time curve from the time of dosing to time extrapolated to infinitely
Time frame: Blood sampling during 24 hours after administration
Terminal half-life
Time frame: Blood sampling during 24 hours after administration
Apparent total body clearance after extravascular administration, calculated as Dose/AUCinf
Time frame: Blood sampling during 24 hours after administration
Apparent volume of distribution after extravascular administration, calculated as Dose/(λzㆍAUCinf)
Time frame: Blood sampling during 24 hours after administration
Percent decrease from baseline in integrated gastric acidity for 24-hour interval after dose
Time frame: Blood sampling during 24 hours after administration
Percent of time with intra-gastric pH greater than 4.0 for 24-hour interval after dose
Time frame: Blood sampling during 24 hours after administration
Median intra-gastric pH for 24-hour interval after dose
Time frame: Blood sampling during 24 hours after administration
Percent decrease from baseline in integrated gastric acidity after dose by time intervals
Hanmi Pharmaceutical Company Limited
Industry
A Randomized, Open-label, Single Dose, Crossover Study to Investigate the Effect of Food on the Pharmacokinetics and Pharmacodynamics of HIP1601 40 mg in Healthy Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05492318
Drug-drug Interaction, Heathy Volunteer
Porto, Portugal
View Trial DetailsNCT03363815
Heathy Volunteer
Daytona Beach, Florida, United States
View Trial DetailsNCT07542158
Basal Ganglia Diseases, Brain Diseases
Englewood, New Jersey, United States
View Trial Details